Diversified Trust Co Increases Position in Johnson & Johnson (NYSE:JNJ)
Diversified Trust Co boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 27.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,868 shares of the company’s stock after buying an additional 3,400 shares during the period. Diversified Trust Co’s holdings in Johnson & Johnson were worth $2,099,000 as of its most recent filing with the SEC.
Other institutional investors have also recently modified their holdings of the company. Lenox Wealth Advisors Inc. raised its stake in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at $117,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares in the last quarter. Ullmann Financial Group Inc. bought a new stake in Johnson & Johnson during the first quarter valued at $186,000. Finally, Taylor Wealth Management Partners raised its stake in Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares in the last quarter. 66.06% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) traded up 0.01% during trading on Friday, reaching $133.10. The company’s stock had a trading volume of 4,270,571 shares. The company has a market cap of $357.24 billion, a P/E ratio of 22.52 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The company’s 50 day moving average price is $133.09 and its 200 day moving average price is $126.30.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.74 EPS. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s payout ratio is 56.76%.
ILLEGAL ACTIVITY WARNING: “Diversified Trust Co Increases Position in Johnson & Johnson (NYSE:JNJ)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/13/diversified-trust-co-increases-position-in-johnson-johnson-nysejnj.html.
Several equities research analysts have recently weighed in on JNJ shares. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Jefferies Group LLC reissued a “hold” rating and set a $135.00 price objective (down from $140.00) on shares of Johnson & Johnson in a research note on Sunday, May 14th. Royal Bank Of Canada reissued a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 15th. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective for the company. in a research note on Friday, July 21st. Finally, Barclays PLC reissued an “equal weight” rating and set a $130.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research note on Monday, April 17th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $133.72.
In other news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.